Page 12 - EndoProxy2012_final

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317 6
WILLIAM P. MONTAGUE has been a member of the Board of Directors since 2009 and is a member of
Endo’s Audit Committee, Nominating & Governance Committee and Transactions Committee. Mr. Mon-
tague served as Chief Executive Officer of Mark IV Industries, Inc., a leading global diversified manufacturer
of highly engineered systems and components for transportation infrastructure, vehicles and equipment,
from November 2004 until his retirement on July 31, 2008 and as Director fromMarch 1996. He joined Mark
IV Industries in April 1972 as Treasurer/Controller, serving as Vice President of Finance from May 1974 to
February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996
and then as President from March 1996 to November 2004. Mr. Montague is also a director of Gibraltar
Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial
markets, and in December of 2010, Mr. Montague became a director of International Imaging Materials, Inc.,
a privately held company that manufactures and sells a variety of thermal transfer ribbons and certain
inks. Mr. Montague’s senior leadership experience as Chief Executive Officer and Director of Mark IV
Industries, Inc. brings to the Board operational and business strategy insights and acquisition experience.
His financial experience also brings strong financial and tax expertise to our Board.
DAVID B. NASH, M.D., M.B.A. was appointed to the Board in March 2011 and is a member of Endo’s Com-
pensation Committee. He is the founding dean of the Jefferson School of Population Health, located on the
campus of Thomas Jefferson University in Philadelphia, Pennsylvania, having taken that position in 2008.
Previously, Dr. Nash was the Chairman of the Department of Health Policy of the Jefferson Medical College
from 2003 to 2008. Dr. Nash is internationally recognized for his work in outcomes management, medical
staff development and quality-of-care improvement; his publications have appeared in more than 100 ar-
ticles in major journals. Dr. Nash serves on the Board of Directors and is a member of the Audit Committee
of Humana Inc., one of the nation’s largest publicly traded health and supplemental benefits companies. Dr.
Nash also has served as a member of the Board of Trustees of Catholic Healthcare Partners in Cincinnati,
Ohio. The Board believes that Dr. Nash brings a set of attributes that enhance the Company’s ability to help
people achieve lifelong well-being. Dr. Nash is a widely recognized innovator in an emerging medical disci-
pline that unites population health, health policy, and individual health.
JOSEPH C. SCODARI has been a member of the Board of Directors since 2008 and is Chairman of Endo’s
Compensation Committee and is a member of Endo’s Transactions Committee. Mr. Scodari was Worldwide
Chairman, Pharmaceuticals Group, of Johnson & Johnson, a diversified healthcare company, and a Member
of Johnson & Johnson’s Executive Committee from March 1, 2005 until March 1, 2008. He joined Johnson
& Johnson in 1999 as President of Centocor, Inc., a biotechnology company, when Johnson & Johnson ac-
quired Centocor. At the time of that acquisition, he had been the President and Chief Operating Officer of
Centocor and a member of Centocor’s Board of Directors since December 1997. In 2001, he was named
Johnson & Johnson’s Company Group Chairman for the North American pharmaceutical business, and be-
came a member of the Johnson & Johnson Pharmaceuticals Group Operating Committee. In 2003, Mr. Sco-
dari was named Johnson & Johnson Company Group Chairman, Global Biopharmaceutical Business. Mr.
Scodari serves as a Non-Executive Director, chairs the Corporate Governance Committee and is a member
of the Compensation Committee of Covance Inc., a publicly traded drug development service company.
Prior to joining Centocor, Mr. Scodari served in various senior leadership roles at Sterling Drug and later,
Rhone-Poulenc Rorer. Mr. Scodari’s years of experience in the pharmaceutical industry and his senior lead-
ership roles as Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson and President of Cen-
tocor bring to the Board extensive knowledge of the pharmaceutical industry as well as organizational and
operational management expertise. Mr. Scodari also contributes valuable business strategy insights. Mr.
Scodari also has extensive corporate governance experience from his services on other company boards.
WILLIAM F. SPENGLER has been a member of the Board of Directors since 2008 and is a member of Endo’s
Audit Committee and Compensation Committee. From November 2010 until February 2012, Mr. Spengler
was President of ChromaDex Corporation, a publicly traded company that is a leader in the development of
phytochemical and botanical reference standards and that discovers, develops and markets novel, natural
ingredients that fill unmet needs for healthy dietary supplements, foods, beverages, cosmetics and pharma-
ceuticals. From October 2011 until February 2012, Mr. Spengler was a member of the ChromaDex Corpora-
tion Board of Directors. From July 2008 until November 2010, Mr. Spengler served as Executive Vice Presi-
dent and Chief Financial Officer of Smith & Wesson Holding Corporation, a global leader in safety, security,
protection and sport. Until March 2008, he was Executive Senior Vice President and Chief Financial Officer
at MGI Pharmaceuticals Inc., an oncology- and acute care-focused biopharmaceutical company, where he
had worked since 2005. Prior to joining MGI Pharma, Mr. Spengler was Executive Vice President and Chief
Financial Officer at Guilford Pharmaceuticals Inc., a bioscience company, from July 2004 to October 2005.
From 2002 to 2004, Mr. Spengler served as President, Chief Operating Officer and Director of Osteoimplant
Technology, Inc., an orthopedic products company. Mr. Spengler was previously a Vice President of Finance
at Black & Decker, and prior to that spent 14 years in various finance, planning and business development
positions at Bristol Myers Squibb. Through his senior executive roles and financial experience at various
organizations, Mr. Spengler contributes expertise in financial analysis, financial statements, evaluation of
business strategies, and brings to the Board valuable leadership and risk management skills.